Ridazolol

Ridazolol
Names
	IUPAC name 5-Chloro-4-[2-[[3-(2-chlorophenoxy)-2-hydroxypropyl]amino]ethylamino]-1H-pyridazin-6-one
Identifiers
CAS Number	83395-21-5 ;
3D model (JSmol)	Interactive image;
ChEMBL	ChEMBL1742443;
ChemSpider	64393;
PubChem CID	71265;
UNII	2R4QO1868Y;
CompTox Dashboard (EPA)	DTXSID301024674 ;
	InChI InChI=1S/C15H18Cl2N4O3/c16-11-3-1-2-4-13(11)24-9-10(22)7-18-5-6-19-12-8-20-21-15(23)14(12)17/h1-4,8,10,18,22H,5-7,9H2,(H2,19,21,23) Key: UUWABVCZFXKHSU-UHFFFAOYSA-N; InChI=1/C15H18Cl2N4O3/c16-11-3-1-2-4-13(11)24-9-10(22)7-18-5-6-19-12-8-20-21-15(23)14(12)17/h1-4,8,10,18,22H,5-7,9H2,(H2,19,21,23) Key: UUWABVCZFXKHSU-UHFFFAOYAL;
	SMILES C1=CC=C(C(=C1)OCC(CNCCNC2=C(C(=O)NN=C2)Cl)O)Cl;
Properties
Chemical formula	C15H18Cl2N4O3
Molar mass	373.23 g·mol−1
	Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). Infobox references

Ridazolol is a pharmaceutical drug acting as a beta adrenergic receptor antagonist. It was investigated in the 1980 and 90s for its effects on coronary heart disease and essential hypertension (high blood pressure).^[1]^[2]

It is not known to be marketed anywhere in the world.^[3]

References

^ Fach, WA; Starke, E; Becker, HJ (1992). "Duration of the effect and dose-response relationship of ridazolol in patients with coronary heart disease". Zeitschrift für Kardiologie. 81 (6): 320–5. PMID 1353933.
^ Rommel, Th.; Demisch, L. (1994). "Influence of chronic ?-adrenoreceptor blocker treatment on melatonin secretion and sleep quality in patients with essential hypertension". Journal of Neural Transmission. 95 (1): 39–48. doi:10.1007/BF01283029. PMID 7857585. S2CID 31936176.
^ "Ridazolol search results". Drugs.com. Retrieved 2021-03-31.

This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it.